drugset / Trial / NCT00551538

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

NCT00551538 ↗

Phase 4 Completed 15 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine if twice-daily Lispro low mixture (75/25) will result in lower post prandial blood glucose readings versus once-daily glargine plus oral diabetic medications.

Timeline

Start
2003-05
Primary completion
—
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lispro mix 75/25 Unknown 23 iu Subcutaneous
Comparator Lispro mix 75/25 Unknown 37 iu Subcutaneous
Comparator insulin glargine Protein / enzyme biologic 44 iu Subcutaneous